In conclusion, our data demonstrate that PI3K‐targeting agents could be effective in the management of micro‐metastatic disease (assessed by cfDNA), in PDAC patients, preventing macro‐metastatic evolution. This evidence concerns the gene PIK3CA and metastatic neoplasm.